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Abstract
Despite their phenotypic heterogeneity, most human prion diseases belong to two broadly defined groups:
Creutzfeldt-Jakob disease (CJD) and Gerstmann-Sträussler-Scheinker disease (GSS). While the structural characteristics of
the disease-related proteinase K-resistant prion protein (resPrPD) associated with the CJD group are fairly well
established, many features of GSS-associated resPrPD are unclear. Electrophoretic profiles of resPrPD associated with GSS
variants typically show 6–8 kDa bands corresponding to the internal PrP fragments as well as a variable number of
higher molecular weight bands, the molecular nature of which has not been investigated. Here we have performed
systematic studies of purified resPrPD species extracted from GSS cases with the A117V (GSSA117V) and F198S (GSSF198S)
PrP gene mutations. The combined analysis based on epitope mapping, deglycosylation treatment and direct amino
acid sequencing by mass spectrometry provided a conclusive evidence that high molecular weight resPrPD species
seen in electrophoretic profiles represent covalently-linked multimers of the internal ~ 7 and ~ 8 kDa fragments. This
finding reveals a mechanism of resPrPD aggregate formation that has not been previously established in prion diseases.
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Introduction
A well-known feature of human prion diseases is the pres-
ence of three distinct etiologic forms - sporadic, inherited
and acquired by infection. A further complicating factor is
the great phenotypic variability within each of these etio-
logically distinct groups. For example, the sporadic form
alone encompasses seven major disease phenotypes [15,
16, 39], and many different variants have been reported
for inherited prion diseases [20, 21]. This phenotypic vari-
ability is believed to be directly related to (and likely
encoded in) distinct strains of the disease-related prion
protein (PrPD). However, the nature and extent of specific
structural differences between phenotype-specific PrPD
strains remain poorly understood [15].
According to the classification based on electrophoretic
profiles of the proteinase K (PK)-resistant PrPD (resPrPD),
most cases of sporadic and inherited prion diseases fall
into two broadly defined groups: Creutzfeldt-Jakob disease
(CJD) and Gerstmann-Sträussler-Scheinker disease (GSS).
CJD is characterized by the presence of relatively large
resPrPD fragments which, depending on the N-terminus,
are classified as type 1 (typically starting at residue G82)
and type 2 (starting at residue S97) [15, 26]. Both fragment
types extend to the C-terminus and include the glycosyl-
phosphatidylinositol (GPI) anchor [16, 39]. Electrophor-
etic profiles of these fragments include bands of
approximately 30 and 27 kDa (representing the di- and
mono-glycosylated forms) as well as bands of 21 and 19
kDa which represent the un-glycosylated form in resPrPD
types 1 and 2, respectively. Collectively, these three
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resPrPD fragments are commonly referred to as PrP 27–
30 [8]. A remarkably different electrophoretic profile is
observed in GSS, where the most prominent and by far
best characterized resPrPD species is a 6–8 kDa fragment
encompassing internal residues from within the ~ 70–150
region [12, 25, 27, 33, 34]. Higher molecular weight
(hmw) bands of variable estimated molecular weights have
also been reported, occasionally prompting the hypothesis
that they represent multimers. However, the molecular na-
ture of the PrP fragments giving rise to these bands re-
mains enigmatic [12, 17, 23].
To bridge this gap, here we have performed detailed
analysis of purified resPrPD preparations from GSS cases
harboring the A117V (GSSA117V) and F198S (GSSF198S)
PrP mutations. Our data demonstrate that high molecular
weight species seen in electrophoretic profiles of GSSA117V
and GSSF198S resPrPD represent covalently-linked multi-
mers of the same internal PrP fragments that are present
(as monomers) in the ~ 7 and ~ 8 kDa bands.
Materials and methods
Reagents and antibodies
β–mercaptoethanol, Dithiothreitol, Laemmli Sample Buf-
fer, Non-fat dry milk, Sodium dodecyl sulfate (SDS), Tris
Buffered Saline (TBS), Tris/Glycine/SDS buffer, Tris/Gly-
cine Buffer, Tween 20 and 15% Criterion Tris-HCl poly-
acrylamide precast gels were purchased from Bio-Rad
Laboratories (Hercules, CA, USA). Benzonase, Calcium
chloride, Complete Ultra Protease Inhibitor Cocktail Tab-
lets, Dulbecco’s PBS (D-PBS), Kodak Biomax MR and
XAR films, NaCl, Nonidet P-40, N-Lauroylsarcosine so-
dium salt solution (Sarkosyl), Phenylmethanesulfonyl
fluoride (PMSF), Polyvinylidene difluoride (PVDF) mem-
brane (Immobilon-P), Proteinase K, Sodium deoxycholate
and Tris-HCl came from MilliporeSigma (Burlington,
MA, USA) whereas Ethylenediaminetetraacetic acid
(EDTA) from Promega (Madison, WI, USA). Glycerol-free
PNGase F was from New England Biolabs Inc. (Ipswich,
MA, USA); Acetonitrile, Colloidal Blue Staining Kit, Etha-
nol, Formic Acid, 8M Guanidine-HCl Solution, Methanol,
Pierce ECL 2 Western Blotting Substrate and Trypsin
from Thermo Fisher Scientific Inc. (Waltham, MA, USA).
The following antibodies (Abs) were used in the study:
8B4 (to human PrP residues 36–43) [22], SAF32 (to hu-
man octarepeat region) [14] (Cayman Chemical, Ann
Arbor, MI, USA), 3F4 (to human PrP residues 106–110)
[19, 42], F89 (to human PrP residues 139–142) (Thermo
Fisher Scientific Inc., Waltham, MA, USA), L42 (to hu-
man PrP residues 145–150) [18, 38] (R-Biopharm, AG,
Darmstadt, Germany) and SAF70 (to human PrP residues
156–162) [14]. Secondary Ab was sheep anti-mouse IgG,
HRP-linked whole antibody (GE Healthcare Life Sciences,
Chicago, IL, USA).
Brain tissues
All frozen brain tissues were obtained from the National
Prion Disease Pathology Surveillance Center (NPDPSC).
Frontal cortex samples from two cases each of GSS
A117V–129V (129MV and 129VV) and F198S-129V
(129MV) were used. All cases were used for immuno-
blotting, but only one case of GSSA117V and GSSF198S,
both with 129MV genotype, were used for mass spec-
trometry. A case of sCJDMV1 was used as control.
Preparation of brain homogenates
Brain homogenates (BH) were prepared as previously
described [13].
Proteinase K digestion
Samples were incubated for 1 h at 37 °C with different
amounts of PK, as follows: GSSA117V: purified PrPD (PK
2 U/ml); GSSF198S: BH (PK 5 U/ml), purified PrPD (PK
10 U/ml); sCJDMV1: purified PrPD (PK 10 U/ml). The
reaction was stopped by the addition of 3 mM PMSF.
Epitope mapping
The optimal PK concentrations and the volumes of puri-
fied GSSF198S, GSSA117V and sCJDMV1 resPrPD loaded
into the gel were selected to obtain a clear visibility of all
the bands with 3F4. Recombinant human PrP full-length
(23–231) and truncated (90–231) species were used as
molecular weight markers.
Methanol/ethanol precipitation
Methanol precipitation was performed as previously de-
scribed [13]. For ethanol precipitation the same procedure
was followed with the exception of 9 volumes of pre-chilled
ethanol instead of 5 volumes used to dilute the sample.
PrP deglycosylation
Samples were treated with glycerol-free PNGase F in ac-
cordance with manufacturer’s instructions.
Electrophoresis and immunoblot
Protein samples were run on 15% Criterion Tris-HCl
polyacrylamide precast gels and then subjected to immu-
noblot (60 V for 2 h) using Immobilon-P PVDF mem-
branes. After 1 h blocking in 5% non-fat dry milk in TBS
with 0.1% Tween 20 (TBS-T), the membranes were in-
cubated with primary Ab overnight at 4 °C; they were
then washed with TBS-T, incubated for 1 h at RT with
the secondary HRP-conjugated Ab and then washed
again prior to developing by enhanced chemilumines-
cence reaction using ECL 2 western blotting substrate,
as per manufacturer’s instructions. Kodak MR and XAR
films were used to capture the signal.
Cracco et al. Acta Neuropathologica Communications             (2019) 7:1 Page 2 of 9
ResPrPD purification
ResPrPD purification was performed as reported in Bol-
ton et al. [7] and adapted by Zou et al. [40]. Rotor
SW55Ti (Beckman Coulter, Brea, CA, USA) was used
for ultracentrifugation.
In-gel trypsin digestion of purified resPrPD
In-gel trypsin digestion was performed according to an
established protocol [31]. Briefly, the protein bands of
interest (visualized by Colloidal Coomassie blue staining)
were excised from the gel, cut into small cubes and
destained. The destained gel pieces were then dehy-
drated and followed by reduction/alkylation step. For di-
gestion, trypsin solution (15 ng/μl) was added and gel
pieces were incubated overnight at 37 °C with shaking.
The supernatant was then transferred into a new Eppen-
dorf tube and the remaining peptides in gel pieces were
extracted, supernatants were pooled, concentrated and
stored at − 80 °C until analyzed by Nano LC-MS.
Nano LC-MS/MS
Nanospray LC-MS-MS analysis was performed using an
LTQ Orbitrap XL mass spectrometer equipped with
nanoelectrospray source (Thermo Scientific, San Jose, CA,
USA). Trypsin-digested samples were loaded onto a C-18
trap column (to remove salts) and separated on a C-18
column connected to an emitter. Separation was per-
formed using a Dionex UltiMate 3000 system (Thermo
Scientific, San Jose, CA, USA) and a gradient of aceto-
nitrile in water containing 0.1% formic acid. The flow rate
was 300 nl/min. The mass spectrometer was externally
calibrated using a Pierce LTQ ESI positive ion calibration
solution (Thermo Scientific, catalog number 88322). Full
scan experiments were acquired in the m/z 300–1800
range at a resolution of 30,000 (FWHM at m/z 400). The
following source settings were used: spray voltage = 4.2
kV; capillary temperature = 200 °C. Data-dependent MSn
(n = 2) were acquired at ITMS using collision induced dis-
sociation (CID); the top 14 intense ions were subjected for
further fragmentation. Calculation of elemental formulae
was performed on the mono-isotopic peak of each ion
cluster using Xcalibur software v2.2 with a mass tolerance
of 3 to 5 ppm. MS/MS raw files were searched using
MASCOT Deamon engine against the database contain-
ing sequence of human prion protein 129M/V with muta-
tion A117V or F198S. Trypsin/P search parameters for
Mascot peptide identification included one missed tryptic
cleavage, fixed carbamidomethylation (+ 57Da, Cys), and
variable oxidation (+ 16Da, Met). Mass tolerances of 2.0
and 1.0 Da were used for parent and monoisotopic frag-
ment ions, respectively. The resulting files generated by
MASCOT were used for peptide identification with the
constraints that only MASCOT ion scores greater than 10
were considered. The percentage of 129M and 129V PrP
in resPrPD samples was calculated by the spectral count-
ing method [4].
Results
The characteristics of resPrPD in GSSF198S and GSSA117V
were examined and compared with those of sCJDMV1
resPrPD, used as control, by combining epitope mapping
with enzymatic deglycosylation on immunoblots of purified
resPrPD preparations (Fig. 1). Overall, GSSF198S and
GSSA117V showed similar electrophoretic profiles that were
easily distinguishable from the profile of sCJDMV1 (Fig. 1).
GSSF198S and GSSA117V displayed low mw bands of ~ 8 and
~ 7 kDa as well as two broad bands comprised between
17-20 23–24 kDa for GSSF198S, and 16–18 and 22–23 kDa
for GSSA117V; additional bands and smears of higher mw
were also present more prominently in GSSF198S (Fig. 1). By
contrast, resPrPD profile in sCJDMV1 included the typical
three glycoform bands of ~ 30, ~ 27, and ~ 21 kDa of
resPrPD type 1. Two additional unique characteristics fur-
ther distinguished GSSA117V and GSSF198S from sCJDMV1.
Virtually all resPrPD bands associated with these two GSS
conditions were readily detected only with Abs to epitopes
within the PrP ~ 51–150 region, but not with Abs recogniz-
ing more C-terminal epitopes (Fig. 1, panels b-f). Further-
more, GSSA117V and GSSF198S resPrPD (as well as resPrPD
from sCJDMV1) showed no immunoreactivity with 8B4 Ab
that recognizes the N-terminal epitope 36–43 (Fig. 1, panel
a). This finding excludes the presence of full length resPrPD
in these two GSS variants, and is at variance with the pres-
ence of full-length resPrPD reported in GSSH187R [12]. In
addition to epitope mapping, a second major distinguishing
feature was that, in contrast to sCJDMV1 resPrPD, deglyco-
sylation had no significant effect on the electrophoretic mo-
bility of any of the major resPrPD bands observed in
GSSF198S and GSSA117V, strongly suggesting that resPrPD
populating these bands is not glycosylated (Fig. 1). In a sep-
arate experiment carried out in GSSF198S, we also observed
that the resPrPD profile did not change after pretreatment
of samples with strong denaturants such as guanidine
hydrochloride and urea (Additional file 1: Figure S1). Col-
lectively, these data suggest that at least two hmw bands
seen in immunoblots of GSSA117V and GSSF198S resPrPD
represent covalently-linked multimers of the ~ 7 and ~ 8
kDa fragments (Fig. 1 and Additional file 1: Figure S1).
To definitely assess whether the higher molecular
bands represented multimers (likely covalently-linked) of
the ~ 7 and ~ 8 kDa internal fragments, as our epitope
mapping and glycosylation study strongly suggested, we
performed trypsin in-gel digestion of protein fragments
on individual electrophoretic bands of purified resPrPD
from GSSA117V and GSSF198S (~ 7, 16–18 and 22–23 kDa
in the case of GSSA117V and ~ 8, 17–20 and 23–24 kDa
in the case of GSSF198S) and did amino acid sequencing
using mass spectrometry (Nano LC-MS).
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The tryptic digest of the ~ 7 kDa resPrPD fragment ex-
tracted from GSSA117V and analyzed by Nano LC-MS re-
vealed the presence of peptides exclusively from the
central region of PrP between residues 78 and 152, with
no detectable fragments from other parts of the protein.
Trypsin is known to cleave polypeptide chains at the
carboxyl side of lysine (K) or arginine (R). As shown in
Fig. 2, seven potential trypsin cleavage sites are available
within the central region of PrP between residues 70 and
153. Nano LC-MS analysis of the GSSA117V ~ 7 kDa frag-
ment using the Mascot Deamon searching engine identi-
fied fourteen trypsin-generated peptides with N-termini
before the first potential trypsin cleavage site, two in-
ternal tryptic fragments, and twelve trypsin-generated
peptides with N-terminus at the cleavage site following
R136 (Fig. 2a and Additional file 2: Table S1). Altogether,
these data demonstrated that in GSSA117V the ~ 7 kDa
fragment encompassed residues within the 78–152 re-
gion and had ragged N- and C-termini corresponding to
residues 78/82/85–88 and 141–152, respectively. This is
generally consistent with previous MALDI-derived data
from extracts of PrP amyloid plaque cores, even though
our Nano LC-MS analysis (which is more accurate) re-
vealed that the N-terminus of this fragment may extend
as far as up to residue 78 versus residue 85 previously
reported based on the MALDI analysis [33].
A similar sequencing analysis of the 16–18 kDa and
22–23 kDa bands revealed the presence of essentially
identical tryptic fragments, with the exception that the
most N-terminal fragment started at residue 82, and the
Fig. 1 Epitope mapping combined with deglycosylation of purified resPrPD associated with GSSF198S, GSSA117V and sCJDMV1 used as control.
PNGase F-treated or untreated, PK-resistant PrPD (resPrPD) purified (see Materials and Methods) from GSSF198S, GSSA117V and sCJDMV1 control
were blotted and probed with the Abs to PrP denoted, with their epitopes, at the top of each panel. Panel a: Only full-length (PK-untreated)
recombinant PrP (23–231) was detected by this Ab to the proximal N-terminal region confirming the absence of resPrPD with complete N-
terminus. Panels b to e: Both GSSF198S and GSSA117V resPrPD conformers were selectively detected by the same Abs to PrP N- and C-terminal
regions; both also showed no major variation of the resPrPD banding pattern following deglycosylation indicating that most of the resPrPD is
unglycosylated in both conditions. Although overall similar, the two resPrPD profiles differed especially in the higher molecular weight region
suggesting a distinct repertoire, or relative proportions, of polymers in the two GSS variants. The GSS banding patterns clearly differed from the
three-band pattern of sCJDMV1, two of which are glycosylated (See Results for detailed description). Panel c includes the bands of both 23–231
and 90–231 recombinant PrP which have been used as molecular weight markers. In b the portion of the panel with the GSSA117V samples
required longer exposure. In panel f, * indicates the 13 kDa component of the glycosylated and anchor bearing PrP 12/13 C-terminus fragments
with N-termini at residues 162–167 and 154–156, respectively [24, 41]
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most C-terminal fragment ended at residue 150 (Fig. 2a).
Remarkably, we could not detect any tryptic peptides from
the region C-terminal to residue 150. Given that numer-
ous peptides from the latter region are readily detectable
by MS upon proteolytic digestion of resPrPD from sCJD
cases and mouse prion strains [1, 30], one can definitely
conclude from these data that the 16–18 and 22–23 kDa
species in GSSA117V resPrPD indeed represent oligomers
(likely trimers and tetramers, respectively) of internal frag-
ments encompassing residues within the 82–150 region. It
is of note that fragments in the oligomers are somewhat
shorter compared to those in the ~ 7 kDa band.
MS-based sequencing analysis of protein present in
the resPrPD ~ 8 kDa band from GSSF198S demonstrated
that this band contained rugged internal resPrPD frag-
ments from the 70–152 region, with N-termini between
residues 70 and 90 and C-termini between residues 141
and 152 (Fig. 2b and Additional file 2: Table S2). Again,
MS analysis did not reveal the presence of peptides from
parts of PrP other than the central region between resi-
dues 70 and 152. Previous sequencing studies of the ~ 8
kDa fragment (or fragments of similar kDa) extracted
from PrP amyloid plaques and analyzed by Edman deg-
radation chemistry alone or combined with automated
sequencing identified the major N-terminus at residues
G58, G74 and G81 while the C-terminus was reported at
residue 150 [27, 34, 35].
Very similar internal fragments were identified in
higher molecular bands of 17–20 and 23–24 kDa in
GSSF198S resPrPD, with the exception that the longest of
these fragments had N-termini at residue 74 and 78 in
the 17–20 and 23–24 kDa bands, respectively (Fig. 2b).
Importantly, akin to the finding for GSSA117V resPrPD,
no peptides from the region C-terminal to residue 152
were detected by MS in tryptic digests of protein in
these two higher molecular weight bands. Thus, also in
GSSF198S resPrPD, the latter bands contained
covalently-linked oligomers of the internal PrP frag-
ments within the 74–78/142–152 region, which, as in
GSSA117V, are somewhat shorter than the ~ 8 kDa
monomer.
Using Nano LC-MS we also determined the relative rep-
resentation in resPrPD of the 129M and 129V polymorphic
forms of the prion protein. Consistent with a previous re-
port, resPrPD from GSSA117V was invariably 100% 129V,
with no detectable 129M polymorph [33]. By contrast, and
at variance with a previous report, in GSSF198S resPrPD, all
three bands examined consistently showed the presence of
Fig. 2 Mass spectrometry (MS)-based sequencing of PrP fragments in the material extracted from individual gel bands of two GSS variants.
GSSA117V resPrPD (a) and GSSF198S resPrPD (b). The material present in these bands was subjected to trypsin digestion, followed by MS analysis of
tryptic fragments. The fragments identified by MS for species extracted from individual gel bands are shown as blue, red and green lines. Amino
acid sequence within the 70-152 region is shown above the lines. Residues marked in red represent potential cleavage sites in the relevant
region of PrP; 129M/V polymorphic residues are marked in blue
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both polymorphic variants, with a large dominance (76–
88%) of the 129V polymorph (Fig. 3) [35].
Discussion
The present results indicate that the mechanism of resPrPD
aggregation in GSSA117V and GSSF198S involves formation
of covalently-linked multimers of the ~7-8 kDa internal
fragments. Furthermore, it has been previously shown by
Edman degradation chemistry that the 7 and 14 kDa frag-
ments in GSSH187R resPrPD share the N-terminus, suggest-
ing that formation of covalently-linked multimers may also
take place in the latter GSS variant [12]. PrP bands suggest-
ive of dimerization have been reported in cell systems and
brain tissues [13, 29]. However, the resistance to PK diges-
tion of these PrP species and, more importantly, their mo-
lecular nature have not been determined. In this context,
the present data provide the strongest evidence to date for
the presence of covalently cross-linked species of resPrPD
in prion diseases, suggesting that these previously
unrecognized species may play a major role in the patho-
genesis of human prion diseases. Of note, covalent cross-
linking has been reported for toxic aggregates of
α-synuclein and Aβ involved in Parkinson’s and Alzhei-
mer’s diseases, respectively [2, 3, 9, 10, 32].
This novel finding has important implications for under-
standing phenotypic variability in human prion diseases.
Even though resPrPD aggregates associated with both CJD
and GSS phenotypes have been shown to be transmissible,
the dramatic difference between these species suggests fun-
damentally different structural mechanisms of prion pro-
tein conformational conversion in GSS as compared with
those in CJD [6, 28]. Indeed, the absence of the constraints
imposed by glycans and the GPI anchor (that are missing
in ~ 7–8 kDa fragments and their covalently-linked multi-
mers) is likely to allow for different types of resPrPD assem-
blies. A potential structural model for the ~ 7–8 kDa
fragments and their multimers is provided by synthetic
amyloid fibrils generated from PrP23–144, a protein match-
ing the sequence of the C-terminally truncated PrP har-
bored in GSSY145Stop [11, 17]. These synthetic amyloid
fibrils adopt a parallel in-register β-structure [36] that is
fundamentally different from the 4-rung solenoid model
proposed for the CJD-associated resPrPD [5, 37]. Remark-
ably, diseased mice inoculated with PrP23–144 fibrils accu-
mulate GSS-like resPrPD aggregates (consisting of ~ 7 kDa
fragment) that likely share the structural motif of amyloid
fibrils used as the inoculum [11].
The nature of the covalent crosslinks between PrP frag-
ments and the residues involved in these crosslinks are at
present unknown. However, our data strongly suggest that
at least two different types of linkages (between different
residues) are likely involved in coupling the monomers that
form trimers and tetramers, since a single linkage type
would preclude mass spectrometric identification of all
tryptic fragments from the ~ 80–150 region.
Although the basic structural characteristics and mode
of aggregation of resPrPD in GSSA117V and GSSF198S ap-
pear to be similar, at least two features distinguish these
two conditions. First, substantially more resPrPD popu-
lates the hmw regions of the immunoblot in GSSF198S than
in GSSA117V, suggesting a stronger propensity for covalent
polymerization in GSSF198S. Second, resPrPD associated
with GSSA117V consists solely of fragments containing the
129V polymorphic form of PrP, whereas both polymorphs
are present in GSSF198S, even though the 129V form
Fig. 3 Relative abundance of 129M and 129V PrP variants in resPrPD
associated with GSSA117V and GSSF198S. a: GSSA117V; b: GSSF198S. The
relative abundance of resPrPD with M or V at residue 129 reflects the
representation of the PrP mutation, which is coupled with the 129V
in both GSS variants. Approximately 10–25% of resPrPD could be
identified as non-mutated (wild type) in GSSF198S while only
mutated resPrPD could be detected in GSSA117V. The relative
populations were determined by mass spectrometry using the
spectral counting method
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predominates. Since pathogenic mutations in both GSS
variants are on the background of 129V PrP, this implies
that resPrPD in GSSF198S contains internal PrP fragments
derived both from both the mutant as well as wild-type
proteins. By contrast, the internal PrP fragments populat-
ing GSSA117V resPrPD represent exclusively the mutant
protein. This suggests that the A117V mutation (which is
within the PK-resistant fragments) may impede the tem-
plated conversion of wild type PrP. No such impediment
would be expected in GSSF198S where the pathogenic mu-
tation is outside the PK-resistant region.
Recently, a novel eight-residue insertion in the hydro-
phobic region of PrP has been associated with a GSS
phenotype [23]. Brains of transgenic mice harboring the
corresponding mouse insertion variation revealed the
presence of a 8 kDa resPrPD fragment similar to those
observed in other GSS variants as well as a 16 kDa
thermolysin-resistant fragment mapping to residues ~
23–155. Based on this finding and other data, it was sug-
gested that the 8 kDa internal fragment derived from the
N-terminal truncation of the 16 kDa fragment and that
this mechanism was shared by other GSS variants. While
this hypothesis may apply to the mouse model and, pos-
sibly, to this specific GSS insertion variant, our demon-
stration that hmw bands harbor oligomers of the ~ 7
and ~ 8 kDa fragments in GSSA117V and GSSF198S (and
possibly GSSH187R) makes the proposed mechanism not
applicable to these GSS variants.
Conclusion
We demonstrated for the first time that the formation of
multimers of a small internal fragment is the primary
mechanism of prion aggregation in GSSA117V and GSSF198S,
two classical variants of Gerstmann-Sträussler-Scheinker
disease (GSS). Prion aggregation by covalently-linked multi-
mer formation from a small glycan- and GPI-free fragment
is likely to allow for novel prion assembles. This finding
opens new horizons and likely will stimulate new research.
Covalently-linked multimers formation has been reported
in other neurodegenerative diseases such as Parkinson’s
and Alzheimer’s diseases.
Additional files
Additional file 1: Figure S1. Further biochemical characterization of
resPrPD associated with GSSF198S. Lane 1: PNGase F-deglycosylated
resPrPD from brain homogenate immunoblotted with 3F4 following
standard conditions. Lane 2: with additional boiling, freezing-thawing and
sonication pre-deglycosylation; lane 3: 41 h PNGase F treatment; lanes 4–
7: incubation with strong denaturants, 8 M urea (after ethanol or metha-
nol precipitation, lanes 4, 5) and 8 M guanidine hydrochloride at 80 °C
(after ethanol or methanol precipitation, lanes 6, 7) pre-deglycosylation.
Treatments had no detectable effect on the resPrPD electrophoretic pro-
file. (TIF 17802 kb)
Additional file 2: Table S1. Tryptic peptides identified for ~ 7 KDa band in
GSSA117V resPrPD. Residue at position 129 is marked in blue. Table S2. Tryptic
peptides identified for ~ 8 KDa band in GSSF198S resPrPD. (PDF 122 kb)
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